Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale

This study aimed to assess the prognostic value of the THRIVE scale in patients aged ≥ 60 years with acute ischemic stroke (AIS) after intravenous thrombolysis with the non-immunogenic staphylokinase compared with alteplase. The post-hoc analysis of FRIDA trial results was performed and enrolled patients aged ≥ 60 years were divided into two groups in accordance with the modified Rankin scale (mRS) score on day 90: good-outcome (mRS 0–2) and poor-outcome (mRS 3–6) groups. The receiver operating characteristic (ROC) curves were compared using Delong test. For all-cause mortality on day 90 the predicted AUC value by the THRIVE scale was 0.8 (0.71–0.9) in the non-immunogenic staphylokinase group and 0.76 (0.66–0.87) in the alteplase group (p = 0.57). For poor outcome, AUC value was 0.73 (0.64–0.82) in the non-immunogenic staphylokinase group and 0.79 (0.71–0.87) in alteplase group (p = 0.36). Thus, our study confirmed the prognostic value of the THRIVE scale to predict the outcomes of the patients aged ≥ 60 years treated with the non-immunogenic staphylokinase. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.